Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04175977 · ClinicalTrials.gov registry record · NA
The Hospice Advanced Dementia Symptom Management and Quality of Life Trial (HAS-QOL)
A NA study, sponsored by NYU Langone Health.
- Completed
- Registry status
- NA
- Development phase
- 44,143
- Enrollment target
NCT04175977: Completed NA study, sponsored by NYU Langone Health.
NCT04175977 is a NA study that has completed, run by NYU Langone Health. The registered enrollment target is 44,143 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (3046% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04175977, a NA study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 44,143 participants
- Enrollment target
Study Summary
The Aliviado Dementia Care Program (formerly known as the Dementia Symptom Management at Home Program, or DSM-H) was developed to implement dementia friendly care for persons with Dementia and their caregivers living in the community. Aliviado Dementia Care-Hospice Edition is a systems level quality assurance performance improvement program that includes interdisciplinary team training, validated assessment instruments, patient-centered care plans, treatment algorithms for behavioral and psychological symptoms of dementia and terminal delirium, and caregiver education pamphlets. Utilizing the R61/R33 mechanism, the Aliviado Dementia Care-Hospice Edition was successfully implemented in 2 sequential pilot trials in the hospice setting in 2019 (R61 phase). Following the successful pilot trials and the attainment of the R61 milestones, the investigators now seek to test the effectiveness of Aliviado Dementia Care-Hospice Edition in a pragmatic RCT in 25 hospice agencies across the nation (R33 phase) on its ability to reduce antipsychotic use (primary outcome) and effect quality (secondary and exploratory outcomes).
Primary Outcome
Antipsychotic use measured using medical records.
Interventions
- BEHAVIORAL Usual Care
- BEHAVIORAL Aliviado Dementia Care-Hospice Edition QAPI program
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44,143 participants |
| Start Date | 2020-01-01 |
| Est. Completion | 2024-08-13 |
| Phase | NA |
What the finished NCT04175977 record still lists
NCT04175977 is an interventional study that assigns participants to a tested intervention. Its 44,143 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (3046% higher).
The record links to 0 conditions, and to 2 interventions - of which Usual Care is the first listed.
NCT04175977 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04175977 about?
NCT04175977 is a clinical study titled "The Hospice Advanced Dementia Symptom Management and Quality of Life Trial (HAS-QOL)". The Aliviado Dementia Care Program (formerly known as the Dementia Symptom Management at Home Program, or DSM-H) was developed to implement dementia friendly care for persons with Dementia and their caregivers living in the community. Aliviado Dementia Care-Hospice Edition is a systems level quality...
What is the current status of trial NCT04175977?
This trial is currently completed. It is a NA study. The enrollment target is 44,143 participants. The study started on 2020-01-01. Estimated completion is 2024-08-13.
What interventions are being tested in trial NCT04175977?
The interventions under investigation include: Usual Care (BEHAVIORAL), Aliviado Dementia Care-Hospice Edition QAPI program (BEHAVIORAL).
Who is sponsoring clinical trial NCT04175977?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04175977's enrollment target sits among peer trials
44,143 7th of 2000 higher than 1,994 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05607732 · 45,257 participants · NA
Primary Care Detection of Cognitive Impairment Leveraging Health & Consumer Technologies in Underserved Communities: The MyCog Trial
- NCT06824350 · 45,450 participants · NA
Clean Trial - Chlorination to Reduce Enteric and Antibiotic Resistant Infections in Neonates
- NCT06597968 · 45,991 participants
Evaluating the Real World Performance of an AI Based Lung Nodule Detection Tool
- NCT03977402 · 47,500 participants
Total Cancer Care Protocol: A Lifetime Partnership With Patients Who Have or May be at Risk of Having Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI